Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA ...

Moderna (MRNA) has clearly outperformed after announcing an Oct. 24 presentation that will include additional late-stage trial data for its cancer shot developed with Merck (MRK), even as analysts ...

Learn how personalized cancer vaccines work and what to watch for at ESMO 2026. A vaccine made from a person’s own tumor has become the first of its kind to succeed in a phase 3 trial. Full results ...

Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share ...

A personalized mRNA cancer vaccine combined with the immunotherapy Keytruda succeeded in a late-stage trial for the deadly skin cancer melanoma, its makers said Wednesday, potentially opening up a new ...

Shares of vaccine maker Moderna ($MRNA) rose by about 4.5% in Thursday trading as investors looked ahead to an October 24 presentation of detailed cancer trial ...

His comments come after Merck officially opened its new 120,000-square-foot research facility in the Greater Philadelphia ...

Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with Bernstein, highlighting its mRNA platform, personalized cancer vaccine program ...

A former Senior Publishing Editor on the Dow Jones Newswires team at The Wall Street Journal, Aaron earned a Bachelor's degree in Economics from the University of Michigan and a Master's in Journalism ...

The personalized cancer vaccine being developed by Moderna and Merck has boosted hopes that mRNA technology could open up a new avenue of treatment, but the available evidence is still limited.